Core E - Virology, Next-Generation Sequencing and Imaging Core E is the main resource provided by the CFAR to support virological investigations of HIV/SIV and studies of its co-pathogens, such as Mycobacterium tuberculosis (Mtb) and Hepatitis C Virus (HCV). The Core has been configured to provide a wide range of services in support of modern virology research that now includes novel services for the rapid creation of recombinant viruses, production of recombinant virus and lentivirus vector stocks, support of shRNA library screens, high throughput, next-generation DNA sequencing (NGS). and access to high resolution fluorescence and electron microscopy technologies.
The specific aims of the Virology, Next Generation Sequencing and Imaging core are: ? Virology: To provide access to panels of primary and recombinant HIV and SIV strains and recombinant yeast technology to create novel viral variants. The core maintains a repository of over 500 well- characterized primary HIV isolates as well as common and novel recombinant laboratory proviral constructs. Ongoing services include HIV, SIV, and lentiviral vector production and assay, provided on a per protocol basis. The core will also provide support for new technologies for shRNA library screens, which are in demand by numerous CFAR supported laboratories. ? Next Generation Sequencing (NGS): Provide access to the latest technologies in ultra-deep sequencing, including Ion Torrent, Roche 454, and Illumina platforms, in a CLIA/CAP (Clinical Laboratory Improvement Amendments/College of American Pathologists) accredited laboratory. In addition to offering the only deep sequencing-based HIV-1 Genotyping and Coreceptor Tropism Assay currently commercially available worldwide (DEEPGEN?HIV), the core has ample expertise and offers training in library preparation and assessment, sequencing, and bioinformatic analysis for both basic and clinical research projects. ? Imaging: Provide access and support for state-of-the-art fluorescence and electron microscopy across multiple platforms. The core houses a Deltavision fluorescence microscopy system within a biocontainment laboratory for live-cell experiments on HIV infected samples. The core supports other imaging platforms through strategic investments in Case imaging facilities to facilitate cross-campus collaborative interactions. In summary, Core E is provides invaluable support for HIV-1 projects involving molecular and cellular virology. The Core is continuously pushing forward new technologies that are not accessible to individual laboratories due to their high cost or degree of specialization. The Core will continue to extensive training and advice to its users and advance new technologies that fulfill unmet needs for the current and future HIV research priorities of the Case/UH CFAR.

Public Health Relevance

Core E The HIV/AIDS pandemic is the single largest threat to global public health. This core provides essential tools in support of basic and clinical research in the Case/UH CFAR, including provision of HIV isolates and state- of-the-art microscopy and DNA sequencing technologies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
3P30AI036219-25S1
Application #
10155685
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Beaubien, Candice M
Project Start
Project End
Budget Start
2019-05-01
Budget End
2020-04-30
Support Year
25
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Tomas, Myreen E; Mana, Thriveen S C; Wilson, Brigid M et al. (2018) Tapering Courses of Oral Vancomycin Induce Persistent Disruption of the Microbiota That Provide Colonization Resistance to Clostridium difficile and Vancomycin-Resistant Enterococci in Mice. Antimicrob Agents Chemother 62:
Yanik, Elizabeth L; Hernández-Ramírez, Raúl U; Qin, Li et al. (2018) Brief Report: Cutaneous Melanoma Risk Among People With HIV in the United States and Canada. J Acquir Immune Defic Syndr 78:499-504
Sahmoudi, Karima; Abbassi, Hassan; Bouklata, Nada et al. (2018) Immune activation and regulatory T cells in Mycobacterium tuberculosis infected lymph nodes. BMC Immunol 19:33
Webel, Allison R; Moore, Shirley M; Longenecker, Chris T et al. (2018) Randomized Controlled Trial of the SystemCHANGE Intervention on Behaviors Related to Cardiovascular Risk in HIV+ Adults. J Acquir Immune Defic Syndr 78:23-33
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
Eckard, Allison Ross; O'Riordan, Mary Ann; Rosebush, Julia C et al. (2018) Vitamin D supplementation decreases immune activation and exhaustion in HIV-1-infected youth. Antivir Ther 23:315-324
Webel, Allison R; Perazzo, Joseph; Longenecker, Christopher T et al. (2018) The Influence of Exercise on Cardiovascular Health in Sedentary Adults With Human Immunodeficiency Virus. J Cardiovasc Nurs 33:239-247
Yan, Junpeng; Shun, Ming-Chieh; Hao, Caili et al. (2018) HIV-1 Vpr Reprograms CLR4DCAF1 E3 Ubiquitin Ligase to Antagonize Exonuclease 1-Mediated Restriction of HIV-1 Infection. MBio 9:
Silver, Nicholas; Paynter, Mary; McAllister, Georgina et al. (2018) Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay. AIDS Res Ther 15:18
Jiang, Wei; Luo, Zhenwu; Martin, Lisa et al. (2018) Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy. Curr HIV Res 16:143-150

Showing the most recent 10 out of 539 publications